Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18-11-2020
Postmodern Studio / Shutterstock.com
The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu (trastuzumab deruxtecan) breast cancer treatment.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PTAB, AstraZeneca, Daiichi Sankyo, Enhertu, US District Court for the Eastern District of Texas